Orchid says US FDA has closed PADE inspection

By Staff reporter

- Last updated on GMT


Related tags Bombay stock exchange Pharmaceutical drug

Orchid Pharma Ltd has received an Establishment Inspection Report (EIR) from the US FDA for its Chennai facility.

The Indian drug firm shared details in a Bombay Stock Exchange (BSE) filing yesterday​, telling investors it is “pleased to inform that Orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection​.”

The US Food and Drug Administration (FDA) team visited Orchid’s headquarters in Nungambakkam, Chennai in June to conduct a post-marketing adverse drug experience reporting inspection (PADE​).


Orchid is currently going through bankruptcy proceedings initiated against it by investors last August.

A resolution professional (RP) appointed in October​ to manage the insolvency process is assessing solutions to Orchid's financial woes, including seeking expressions of interest from companies interested in a takeover.

In December, Aurobindo Pharma Limited denied rumours it is interested in buying Orchid telling​ the Bombay stock Exchange (BSE) an Economic Times story ​ suggesting it is one of seven firms looking at Orchid is “factually incorrect.”

Dr Reddy's, which was also rumoured to be a potential suitor, told​ the BSE the reports are “purely speculative.”

Orchid Assets

Orchid makes injectable drugs and active pharmaceutical ingredients (API) for the domestic and export markets.

The Nungambakkam-headquartered firm has ingredient plants in Alathur, Chennai and a finished dosage form site in neighbouring Irungattukottai.

According to its website – have all passed inspections by the US Food and Drug Administration (FDA) and the UK MHRA.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more